Predictive Genetic Testing and Consumer Genomics Market Report 2026

The predictive genetic testing and consumer genomics market size has grown rapidly in recent years. It will grow from $9.07 billion in 2025 to $10.49 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to growth of consumer health awareness, expansion of genetic testing accessibility, rising availability of affordable sequencing technologies, increasing interest in ancestry testing, development of digital health ecosystems.

The predictive genetic testing and consumer genomics market size is expected to see rapid growth in the next few years. It will grow to $18.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing demand for personalized preventive healthcare, rising adoption of pharmacogenomic testing, expansion of consumer genomics platforms, growing integration with digital health apps, increasing regulatory oversight on genetic data usage. Major trends in the forecast period include increasing adoption of direct-to-consumer genetic testing, rising use of digital health platforms, growing demand for preventive health insights, expansion of at-home sample collection kits, enhanced focus on data privacy and security.

The growing awareness of personalized medicine is expected to drive the growth of the predictive genetic testing and consumer genomics market going forward. Personalized medicine is a medical approach that tailors treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental factors. Awareness of personalized medicine is increasing because it enhances treatment effectiveness by aligning therapies with a patient’s unique biological characteristics. Predictive genetic testing and consumer genomics support personalized medicine by identifying genetic risks and traits, enabling individualized prevention, early diagnosis, and treatment strategies based on a person’s genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, up from 6 in 2022. Therefore, the rising awareness of personalized medicine is propelling the growth of the predictive genetic testing and consumer genomics market.

Key companies operating in the predictive genetic testing and consumer genomics market are focusing on technological innovations such as high-throughput, cost-efficient sequencing to enable large-scale, accurate, and affordable genomic analysis. High-throughput and cost-efficient sequencing refers to the ability to process a large number of genomes quickly while reducing per-genome costs, making population-level testing feasible. For instance, in February 2024, Ultima Genomics Inc., a US-based sequencing company, launched its UG 100 sequencing system with ppmSeq extreme-accuracy mode, offering up to 6-8 billion reads per wafer, with dual-wafer runs reaching approximately 4.8 Tb and expected run times under 14 hours. Built with a wafer-based substrate and flexible reagent cartridges, the system supports an industry-leading ~$100-genome roadmap through reagent costs of around $2,000 per wafer. The ppmSeq mode achieves Q60 SNV raw-read accuracy without additional workflow steps. Combining low reagent cost, high automation, and AI-driven variant calling, the UG 100 enables broad applications across consumer genomics, population screening, clinical whole-genome sequencing, pharmacogenomics, and large-scale research. Overall, the platform delivers faster, more scalable, and more affordable genomic data generation compared with legacy NGS technologies.

In April 2025, Illumina Inc., a US-based biotechnology company, partnered with Tempus AI Inc. to accelerate the clinical adoption of precision medicine by integrating advanced genomic artificial intelligence (AI) and multimodal data, making comprehensive molecular profiling a standard component of patient care across multiple disease areas. Tempus AI Inc. is a US-based health technology company that leverages AI-driven genomic analysis to enhance predictive genetic testing and consumer genomics.

Major companies operating in the predictive genetic testing and consumer genomics market are Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, QIAGEN N.V., Ancestry.com, Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, 23andMe Inc., Helix Inc., Color Health Inc., Mapmygenome India Ltd., Reliance Life Sciences, Dante Labs Inc., EasyDNA, Gene by Gene Ltd., Nebula Genomics Inc., Pathway Genomics Corporation.

North America was the largest region in the predictive genetic testing and consumer genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive genetic testing and consumer genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive genetic testing and consumer genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the predictive genetic testing and consumer genomics market by increasing costs of imported sequencing equipment, testing kits, reagents, and digital infrastructure components. Consumer genomics providers in North America and Europe are most affected due to reliance on imported laboratory technologies, while Asia-Pacific faces higher costs in kit manufacturing and exports. These tariffs are increasing service pricing and slowing expansion into price-sensitive markets. However, they are also supporting localized kit production, regional laboratory development, and innovation in cost-efficient testing models.

The predictive genetic testing and consumer genomics market research report is one of a series of new reports that provides predictive genetic testing and consumer genomics market statistics, including predictive genetic testing and consumer genomics industry global market size, regional shares, competitors with a predictive genetic testing and consumer genomics market share, detailed predictive genetic testing and consumer genomics market segments, market trends and opportunities, and any further data you may need to thrive in the predictive genetic testing and consumer genomics industry. This predictive genetic testing and consumer genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Predictive genetic testing and consumer genomics refer to the analysis of an individual’s deoxyribonucleic acid (DNA) to assess their risk of developing certain genetic conditions or traits and to provide personalized health, ancestry, and lifestyle insights. These services are offered directly to consumers or through healthcare providers and use genetic information to guide preventive health decisions or personal interest in genetic heritage.

The primary testing types of predictive genetic testing and consumer genomics include diagnostic testing, predictive testing, pharmacogenomic testing, and carrier screening. Diagnostic testing helps confirm or rule out genetic conditions in individuals already showing symptoms. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray technology, and DNA sequencing. Service types include genetic counseling, sample collection and analysis, and interpretation and reporting of genetic data. Applications span breast and ovarian cancer, cardiovascular screening, diabetic screening and monitoring, colon cancer, Parkinson’s or Alzheimer’s disease, urologic or prostate cancer screening, orthopedic and musculoskeletal conditions, other cancer screenings, and other diseases. Key end users include healthcare providers, research organizations, diagnostic laboratories, and consumers (direct-to-consumer testing).

The predictive genetic testing and consumer genomics market includes revenues earned by entities by providing services such as disease risk assessment, carrier screening, and ancestry and ethnicity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.